尿毒康合剂联合常规治疗对慢性肾脏病患者的临床疗效

Clinical effects of Niaodukang Mixture combined with conventional treatment on patients with chronic kidney disease

目的考察尿毒康合剂联合常规治疗对慢性肾脏病患者的临床疗效。方法58例患者随机分为对照组和观察组,每组29例,对照组给予常规治疗(降压、降脂、抗凝等),观察组在对照组基础上加用尿毒康合剂,疗程8周。检测CR、BUN、eGFR、尿β2微球蛋白、炎症因子(ESR、CRP、TNF-α、IL-6、IL-1β)、血浆内毒素、中医证候评分、中医证候疗效、安全性指标变化。结果治疗后,观察组尿β2微球蛋白、TNF-α、IL-6、中医证候评分降低(P<0.05),中医证候改善总有效率升高(P<0.05),其中IL-6、中医证候评分低于对照组(P<0.05),中医证候改善总有效率更高(P<0.05)。2组未发现严重不良反应,安全性指标无明显异常。结论尿毒康合剂联合常规治疗可安全有效地降低慢性肾脏病患者TNF-α、IL-6水平及中医证候评分,提高中医证候改善总有效率,改善微炎症状态,减轻临床症状。

AIM To investigate the clinical effects of Niaodukang Mixture combined with conventional treatment on patients with chronic kidney disease.METHODS Fifty-eight patients were randomly assigned into control group(29 cases)for 8-week intervention of conventional treatment(anti-hypertension,hypolipidemic,anti-coagulation,etc.),and observation group(29 cases)for 8-week intervention of both intervention and conventional treatment.The changes in CR,BUN,eGFR,urineβ2 microglobulin,inflammatory factors(ESR,CRP,TNF-α,IL-6,IL-1β),plasma endotoxin,TCM syndrome score,TCM syndrome efficacy and safety indices were detected.RESULTS After the treatment,the observation group demonstrated decreased urineβ2 microglobulin,TNF-α,IL-6,TCM syndrome score(P<0.05),and increased total effective rate of TCM syndrome improvement(P<0.05),among which IL-6 and TCM syndrome score were lower than those in the control group(P<0.05),along with higher total effective rate of TCM syndrome improvement(P<0.05).No serious adverse reactions and obviously abnormal safety indices were found in the two groups.CONCLUSION For the patients with chronic kidney disease,Niaodukang Mixture combined with conventional treatment can safely and effectively reduce TNF-α,IL-1βlevels and TCM syndrome score,elevate total effective rate of TCM syndrome improvement,improve micro-inflammatory state and alleviate clinical symptoms.